The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
105829019 10582901 9 F 201406 20160921 20141114 20160926 EXP CA-ROCHE-1423515 ROCHE 54.59 YR M Y 0.00000 20160926 CN CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
105829019 10582901 1 PS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 300 MG SOLUTION FOR INJECTION QOW
105829019 10582901 2 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 3 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 4 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 5 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 6 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 7 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 8 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 9 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 10 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0062,S0066B,S0003C 103976 SOLUTION FOR INJECTION
105829019 10582901 11 C SYMBICORT BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE 1 Unknown U 0
105829019 10582901 12 C ALVESCO CICLESONIDE 1 Unknown U 0
105829019 10582901 13 C SINGULAIR MONTELUKAST SODIUM 1 Unknown U 0
105829019 10582901 14 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 Unknown U 0
105829019 10582901 15 C NASONEX MOMETASONE FUROATE 1 Unknown U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
105829019 10582901 1 Asthma
105829019 10582901 11 Product used for unknown indication
105829019 10582901 12 Product used for unknown indication
105829019 10582901 13 Product used for unknown indication
105829019 10582901 14 Product used for unknown indication
105829019 10582901 15 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
105829019 10582901 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
105829019 10582901 Blood pressure increased
105829019 10582901 Cellulitis
105829019 10582901 Hypersensitivity
105829019 10582901 Lower respiratory tract infection
105829019 10582901 Nasopharyngitis
105829019 10582901 Stress

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
105829019 10582901 1 20101027 0
105829019 10582901 2 20141105 0
105829019 10582901 3 20150804 0
105829019 10582901 4 20151118 0
105829019 10582901 5 20160309 0
105829019 10582901 6 20160504 0
105829019 10582901 7 20160713 0
105829019 10582901 8 20160727 0
105829019 10582901 9 20160907 0
105829019 10582901 10 20160921 0